Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation
T cell alloreactivity against minor histocompatibility antigens (mHAgs)—polymorphic
peptides resulting from donor–recipient (D–R) disparity at sites of genetic polymorphisms …
peptides resulting from donor–recipient (D–R) disparity at sites of genetic polymorphisms …
[HTML][HTML] Minor Histocompatibility Antigens to Predict, Monitor or Manipulate GvL and GvHD after Allogeneic Hematopoietic Cell Transplantation
KJ Fuchs, JHF Falkenburg, M Griffioen - Best Practice & Research Clinical …, 2024 - Elsevier
Allogeneic hematopoietic cell transplantation (alloHCT) provides a potential curative
treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) …
treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) …
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens
KJ Fuchs, M van de Meent, MW Honders, I Khatri… - Blood, 2024 - ashpublications.org
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological
malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells …
malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells …
Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation
M Tamaki, S Kawamura, K Takano, H Nakamae… - Cytotherapy, 2024 - Elsevier
Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient
(female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host …
(female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host …
[PDF][PDF] Falkenburg
K Fuchs - HF, & Griffioen, M, 2024 - scholarlypublications …
Allogeneic hematopoietic cell transplantation (alloHCT) provides a potential curative
treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) …
treatment for haematological malignancies. The therapeutic Graft-versus-Leukaemia (GvL) …
[PDF][PDF] an de, Honders, MW, Khatri, I
K Fuchs, M Meent - Kester, MGD, Koster, E.. S …, 2024 - scholarlypublications …
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological
malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells …
malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells …
[PDF][PDF] Animal models for transplant immunology: bridging bench to bedside
The progress of transplantation has been propelled forward by animal experiments. Animal
models have not only provided opportunities to understand complex immune mechanisms in …
models have not only provided opportunities to understand complex immune mechanisms in …
[PDF][PDF] Interim Technical Report
S Spellman - 2022 - apps.dtic.mil
Contingency Preparedness: Collect information from transplant centers, build awareness of
the Transplant Center Contingency Planning Committee and educate the transplant …
the Transplant Center Contingency Planning Committee and educate the transplant …
Development of Medical Technology for Contingency Response to Marrow Toxic Agents
S Spellman - 2023 - apps.dtic.mil
1. Contingency Preparedness: Collect information from transplant centers, build awareness
of the Transplant Center Contingency Planning Committee and educate the transplant …
of the Transplant Center Contingency Planning Committee and educate the transplant …